Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemnifosbuvir + buprenorphine + naloxone + ruzasvir
- Development stage
- Unknown
- Lead developer
- Atea Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Buprenorphine + naloxone + BEM + RZR is an investigational drug combination being studied for the treatment of chronic Hepatitis C Virus (HCV) infection in patients receiving opioid maintenance therapy. The regimen consists of bemnifosbuvir (BEM, AT-527), an oral nucleotide analog polymerase inhibitor targeting the HCV NS5B polymerase, and ruzasvir (RZR, AT-038), an oral NS5A inhibitor. These antivirals are co-administered with buprenorphine and naloxone, which are standard-of-care medications for opioid use disorder. Developed by Atea Pharmaceuticals, this combination is specifically evaluated in Phase 1 drug-drug interaction (DDI) trials to assess the pharmacokinetic compatibility of the BEM/RZR pan-genotypic HCV regimen with stable opiate maintenance therapy, facilitating the inclusion of this high-prevalence patient population in late-stage clinical trials.
- Other names
- BEM/RZR + buprenorphine/naloxonebemnifosbuvir + ruzasvir + buprenorphine + naloxone
02
Targets
MOR (Mu opioid receptor)KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on bemnifosbuvir + buprenorphine + naloxone + ruzasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemnifosbuvir + buprenorphine + naloxone + ruzasvir.